302 A phase I trial of intratumoral PVSRIPO in patients with unresectable treatment refractory melanoma
Main Authors: | Matthias Gromeier, Georgia Beasley, Nellie Farrow, Karenia Landa, Maria Angelica Seilm, Sin-Ho Jung, Darell Bigner, Andrea True Kelly, Smita Nair, April Salama |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma
by: Matthias Gromeier, et al.
Published: (2021-04-01) -
Examining Peripheral and Tumor Cellular Immunome in Patients With Cancer
by: Eda K. Holl, et al.
Published: (2019-07-01) -
An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect
by: Cho Rong Hong, et al.
Published: (2019-02-01) -
Overall Survival Improved for Contemporary Patients with Melanoma: A 2004–2015 National Cancer Database Analysis
by: Norma E. Farrow, et al.
Published: (2020-05-01) -
Phase 2 trial of hypoxia activated evofosfamide (TH302) for treatment of recurrent bevacizumab-refractory glioblastoma
by: Andrew J. Brenner, et al.
Published: (2021-01-01)